A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Public ClinicalTrials.gov record NCT07318558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
Study identification
- NCT ID
- NCT07318558
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 900 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- Rescue Medications Drug
- Sacituzumab tirumotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2026
- Primary completion
- Feb 24, 2033
- Completion
- Feb 24, 2033
- Last update posted
- May 7, 2026
2026 – 2033
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mount Sinai Cancer Center ( Site 0029) | Miami Beach | Florida | 33140 | Recruiting |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0055) | Fort Wayne | Indiana | 46845 | Recruiting |
| Women's Cancer Care ( Site 0018) | Covington | Louisiana | 70433 | Recruiting |
| Nebraska Methodist Hospital ( Site 0004) | Omaha | Nebraska | 68114 | Recruiting |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007) | Tulsa | Oklahoma | 74146 | Recruiting |
| West Cancer Center and Research Institute ( Site 0013) | Germantown | Tennessee | 38138 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07318558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07318558 live on ClinicalTrials.gov.